nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—RALBP1—Doxorubicin—uterine cancer	0.109	0.206	CbGbCtD
Sorafenib—UGT1A1—Etoposide—uterine cancer	0.0275	0.052	CbGbCtD
Sorafenib—CYP2C8—Medroxyprogesterone Acetate—uterine cancer	0.0271	0.0514	CbGbCtD
Sorafenib—ABCG2—Dactinomycin—uterine cancer	0.0268	0.0507	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Progesterone—uterine cancer	0.0249	0.0472	CbGbCtD
Sorafenib—CYP3A7—Progesterone—uterine cancer	0.0249	0.0472	CbGbCtD
Sorafenib—ABCC2—Carboplatin—uterine cancer	0.0199	0.0377	CbGbCtD
Sorafenib—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.0189	0.0359	CbGbCtD
Sorafenib—CYP3A5—Progesterone—uterine cancer	0.0187	0.0354	CbGbCtD
Sorafenib—ABCG2—Carboplatin—uterine cancer	0.018	0.0341	CbGbCtD
Sorafenib—CYP2C8—Progesterone—uterine cancer	0.018	0.0341	CbGbCtD
Sorafenib—ABCC2—Etoposide—uterine cancer	0.0167	0.0316	CbGbCtD
Sorafenib—ABCG2—Etoposide—uterine cancer	0.0151	0.0286	CbGbCtD
Sorafenib—CYP2C19—Progesterone—uterine cancer	0.0151	0.0286	CbGbCtD
Sorafenib—CYP1A2—Progesterone—uterine cancer	0.0139	0.0264	CbGbCtD
Sorafenib—CYP2C9—Progesterone—uterine cancer	0.0125	0.0238	CbGbCtD
Sorafenib—ABCB1—Progesterone—uterine cancer	0.0122	0.0231	CbGbCtD
Sorafenib—CYP2D6—Progesterone—uterine cancer	0.0115	0.0217	CbGbCtD
Sorafenib—ABCC2—Doxorubicin—uterine cancer	0.0114	0.0216	CbGbCtD
Sorafenib—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.011	0.0208	CbGbCtD
Sorafenib—ABCG2—Doxorubicin—uterine cancer	0.0103	0.0195	CbGbCtD
Sorafenib—ABCB1—Dactinomycin—uterine cancer	0.00965	0.0183	CbGbCtD
Sorafenib—CYP3A5—Etoposide—uterine cancer	0.00837	0.0158	CbGbCtD
Sorafenib—CYP2C8—Etoposide—uterine cancer	0.00804	0.0152	CbGbCtD
Sorafenib—CYP3A4—Progesterone—uterine cancer	0.00729	0.0138	CbGbCtD
Sorafenib—CYP2B6—Doxorubicin—uterine cancer	0.00724	0.0137	CbGbCtD
Sorafenib—CYP1A2—Etoposide—uterine cancer	0.00623	0.0118	CbGbCtD
Sorafenib—ABCB1—Etoposide—uterine cancer	0.00544	0.0103	CbGbCtD
Sorafenib—Regorafenib—FGFR2—uterine cancer	0.005	1	CrCbGaD
Sorafenib—ABCB1—Doxorubicin—uterine cancer	0.00371	0.00704	CbGbCtD
Sorafenib—CYP2D6—Doxorubicin—uterine cancer	0.0035	0.00663	CbGbCtD
Sorafenib—CYP3A4—Etoposide—uterine cancer	0.00326	0.00618	CbGbCtD
Sorafenib—CYP3A4—Doxorubicin—uterine cancer	0.00222	0.00422	CbGbCtD
Sorafenib—FGFR1—uterine cervix—uterine cancer	0.000662	0.005	CbGeAlD
Sorafenib—HIPK3—female reproductive system—uterine cancer	0.000651	0.00492	CbGeAlD
Sorafenib—EPHX2—mammalian vulva—uterine cancer	0.000651	0.00492	CbGeAlD
Sorafenib—BRAF—uterus—uterine cancer	0.000649	0.0049	CbGeAlD
Sorafenib—FLT4—decidua—uterine cancer	0.000639	0.00483	CbGeAlD
Sorafenib—MAP3K19—female reproductive system—uterine cancer	0.000638	0.00482	CbGeAlD
Sorafenib—UGT1A9—renal system—uterine cancer	0.000636	0.00481	CbGeAlD
Sorafenib—STK10—myometrium—uterine cancer	0.000635	0.0048	CbGeAlD
Sorafenib—FGFR1—decidua—uterine cancer	0.000631	0.00477	CbGeAlD
Sorafenib—MAP3K7—uterine cervix—uterine cancer	0.000627	0.00474	CbGeAlD
Sorafenib—EPHX2—uterus—uterine cancer	0.00062	0.00469	CbGeAlD
Sorafenib—CDK7—Daunorubicin—Epirubicin—uterine cancer	0.000614	0.173	CbGdCrCtD
Sorafenib—CDK7—Doxorubicin—Epirubicin—uterine cancer	0.000614	0.173	CbGdCrCtD
Sorafenib—CDK7—Idarubicin—Epirubicin—uterine cancer	0.000614	0.173	CbGdCrCtD
Sorafenib—MKNK2—epithelium—uterine cancer	0.000612	0.00463	CbGeAlD
Sorafenib—MAP3K7—smooth muscle tissue—uterine cancer	0.000609	0.0046	CbGeAlD
Sorafenib—TIE1—female reproductive system—uterine cancer	0.000608	0.0046	CbGeAlD
Sorafenib—MKNK2—uterine cervix—uterine cancer	0.000607	0.00459	CbGeAlD
Sorafenib—ZAK—female gonad—uterine cancer	0.000605	0.00457	CbGeAlD
Sorafenib—ZAK—vagina—uterine cancer	0.000602	0.00455	CbGeAlD
Sorafenib—MKNK1—uterine cervix—uterine cancer	0.0006	0.00453	CbGeAlD
Sorafenib—RET—epithelium—uterine cancer	0.000597	0.00452	CbGeAlD
Sorafenib—MAP3K7—decidua—uterine cancer	0.000597	0.00451	CbGeAlD
Sorafenib—HIPK3—female gonad—uterine cancer	0.000592	0.00448	CbGeAlD
Sorafenib—MKNK2—smooth muscle tissue—uterine cancer	0.00059	0.00446	CbGeAlD
Sorafenib—HIPK3—vagina—uterine cancer	0.000589	0.00445	CbGeAlD
Sorafenib—FGFR1—mammalian vulva—uterine cancer	0.000579	0.00438	CbGeAlD
Sorafenib—MKNK2—decidua—uterine cancer	0.000579	0.00437	CbGeAlD
Sorafenib—MKNK1—decidua—uterine cancer	0.000571	0.00432	CbGeAlD
Sorafenib—MKNK2—renal system—uterine cancer	0.000568	0.00429	CbGeAlD
Sorafenib—CDK7—Epirubicin—Doxorubicin—uterine cancer	0.000568	0.16	CbGdCrCtD
Sorafenib—CDK7—Idarubicin—Doxorubicin—uterine cancer	0.000568	0.16	CbGdCrCtD
Sorafenib—CDK7—Daunorubicin—Doxorubicin—uterine cancer	0.000568	0.16	CbGdCrCtD
Sorafenib—MAP3K7—endometrium—uterine cancer	0.000567	0.00428	CbGeAlD
Sorafenib—MAP2K5—myometrium—uterine cancer	0.000567	0.00428	CbGeAlD
Sorafenib—KDR—myometrium—uterine cancer	0.000567	0.00428	CbGeAlD
Sorafenib—RET—decidua—uterine cancer	0.000564	0.00427	CbGeAlD
Sorafenib—RET—renal system—uterine cancer	0.000554	0.00419	CbGeAlD
Sorafenib—TIE1—female gonad—uterine cancer	0.000553	0.00418	CbGeAlD
Sorafenib—FLT3—female reproductive system—uterine cancer	0.000553	0.00418	CbGeAlD
Sorafenib—CSF1R—myometrium—uterine cancer	0.000553	0.00418	CbGeAlD
Sorafenib—FGFR1—uterus—uterine cancer	0.000552	0.00417	CbGeAlD
Sorafenib—MKNK2—endometrium—uterine cancer	0.000549	0.00415	CbGeAlD
Sorafenib—RALBP1—uterine cervix—uterine cancer	0.000548	0.00415	CbGeAlD
Sorafenib—MAP3K7—mammalian vulva—uterine cancer	0.000548	0.00414	CbGeAlD
Sorafenib—MKNK1—endometrium—uterine cancer	0.000542	0.0041	CbGeAlD
Sorafenib—RALBP1—smooth muscle tissue—uterine cancer	0.000533	0.00403	CbGeAlD
Sorafenib—MKNK2—mammalian vulva—uterine cancer	0.000531	0.00402	CbGeAlD
Sorafenib—BRAF—female gonad—uterine cancer	0.000531	0.00401	CbGeAlD
Sorafenib—BRAF—vagina—uterine cancer	0.000527	0.00399	CbGeAlD
Sorafenib—FLT1—epithelium—uterine cancer	0.000526	0.00398	CbGeAlD
Sorafenib—MKNK1—mammalian vulva—uterine cancer	0.000525	0.00397	CbGeAlD
Sorafenib—RAF1—epithelium—uterine cancer	0.000523	0.00395	CbGeAlD
Sorafenib—RALBP1—decidua—uterine cancer	0.000522	0.00395	CbGeAlD
Sorafenib—MAP3K7—uterus—uterine cancer	0.000522	0.00395	CbGeAlD
Sorafenib—FLT1—uterine cervix—uterine cancer	0.000522	0.00394	CbGeAlD
Sorafenib—RAF1—uterine cervix—uterine cancer	0.000519	0.00392	CbGeAlD
Sorafenib—EPHB6—uterine cervix—uterine cancer	0.000516	0.0039	CbGeAlD
Sorafenib—RALBP1—renal system—uterine cancer	0.000513	0.00388	CbGeAlD
Sorafenib—EPHX2—female gonad—uterine cancer	0.000507	0.00383	CbGeAlD
Sorafenib—FLT1—smooth muscle tissue—uterine cancer	0.000507	0.00383	CbGeAlD
Sorafenib—MKNK2—uterus—uterine cancer	0.000506	0.00383	CbGeAlD
Sorafenib—EPHX2—vagina—uterine cancer	0.000504	0.00381	CbGeAlD
Sorafenib—RAF1—smooth muscle tissue—uterine cancer	0.000504	0.00381	CbGeAlD
Sorafenib—FLT3—female gonad—uterine cancer	0.000504	0.00381	CbGeAlD
Sorafenib—FLT4—female reproductive system—uterine cancer	0.000503	0.0038	CbGeAlD
Sorafenib—KIT—myometrium—uterine cancer	0.000502	0.0038	CbGeAlD
Sorafenib—FLT1—decidua—uterine cancer	0.000497	0.00376	CbGeAlD
Sorafenib—RALBP1—endometrium—uterine cancer	0.000496	0.00375	CbGeAlD
Sorafenib—RAF1—decidua—uterine cancer	0.000494	0.00373	CbGeAlD
Sorafenib—STK10—uterine cervix—uterine cancer	0.000494	0.00373	CbGeAlD
Sorafenib—EPHB6—decidua—uterine cancer	0.000491	0.00371	CbGeAlD
Sorafenib—PDGFRB—myometrium—uterine cancer	0.00049	0.00371	CbGeAlD
Sorafenib—FLT1—renal system—uterine cancer	0.000488	0.00369	CbGeAlD
Sorafenib—RAF1—renal system—uterine cancer	0.000485	0.00367	CbGeAlD
Sorafenib—RALBP1—mammalian vulva—uterine cancer	0.00048	0.00363	CbGeAlD
Sorafenib—PDGFRA—smooth muscle tissue—uterine cancer	0.000475	0.00359	CbGeAlD
Sorafenib—FLT1—endometrium—uterine cancer	0.000472	0.00357	CbGeAlD
Sorafenib—STK10—decidua—uterine cancer	0.00047	0.00356	CbGeAlD
Sorafenib—RAF1—endometrium—uterine cancer	0.000469	0.00355	CbGeAlD
Sorafenib—EPHB6—endometrium—uterine cancer	0.000466	0.00353	CbGeAlD
Sorafenib—PDGFRA—decidua—uterine cancer	0.000466	0.00352	CbGeAlD
Sorafenib—STK10—renal system—uterine cancer	0.000462	0.00349	CbGeAlD
Sorafenib—MAPK11—lymph node—uterine cancer	0.000458	0.00346	CbGeAlD
Sorafenib—FLT4—female gonad—uterine cancer	0.000457	0.00346	CbGeAlD
Sorafenib—PDGFRA—renal system—uterine cancer	0.000457	0.00346	CbGeAlD
Sorafenib—RALBP1—uterus—uterine cancer	0.000457	0.00345	CbGeAlD
Sorafenib—FLT1—mammalian vulva—uterine cancer	0.000456	0.00345	CbGeAlD
Sorafenib—MKNK2—female reproductive system—uterine cancer	0.000455	0.00344	CbGeAlD
Sorafenib—RAF1—mammalian vulva—uterine cancer	0.000454	0.00343	CbGeAlD
Sorafenib—FGFR1—female gonad—uterine cancer	0.000451	0.00341	CbGeAlD
Sorafenib—EPHB6—mammalian vulva—uterine cancer	0.000451	0.00341	CbGeAlD
Sorafenib—CDK7—lymph node—uterine cancer	0.00045	0.0034	CbGeAlD
Sorafenib—MKNK1—female reproductive system—uterine cancer	0.000449	0.0034	CbGeAlD
Sorafenib—FGFR1—vagina—uterine cancer	0.000448	0.00339	CbGeAlD
Sorafenib—TAOK2—lymph node—uterine cancer	0.000447	0.00338	CbGeAlD
Sorafenib—KDR—epithelium—uterine cancer	0.000445	0.00336	CbGeAlD
Sorafenib—AURKC—lymph node—uterine cancer	0.000443	0.00335	CbGeAlD
Sorafenib—KDR—uterine cervix—uterine cancer	0.000441	0.00333	CbGeAlD
Sorafenib—MAP2K5—uterine cervix—uterine cancer	0.000441	0.00333	CbGeAlD
Sorafenib—UGT1A1—renal system—uterine cancer	0.000436	0.0033	CbGeAlD
Sorafenib—FLT1—uterus—uterine cancer	0.000435	0.00329	CbGeAlD
Sorafenib—RAF1—uterus—uterine cancer	0.000432	0.00327	CbGeAlD
Sorafenib—STK10—mammalian vulva—uterine cancer	0.000432	0.00327	CbGeAlD
Sorafenib—CSF1R—uterine cervix—uterine cancer	0.00043	0.00325	CbGeAlD
Sorafenib—KDR—smooth muscle tissue—uterine cancer	0.000429	0.00324	CbGeAlD
Sorafenib—MAP3K7—female gonad—uterine cancer	0.000427	0.00323	CbGeAlD
Sorafenib—MAP3K7—vagina—uterine cancer	0.000425	0.00321	CbGeAlD
Sorafenib—KDR—decidua—uterine cancer	0.00042	0.00318	CbGeAlD
Sorafenib—MAP2K5—decidua—uterine cancer	0.00042	0.00318	CbGeAlD
Sorafenib—CSF1R—smooth muscle tissue—uterine cancer	0.000418	0.00316	CbGeAlD
Sorafenib—MKNK2—female gonad—uterine cancer	0.000414	0.00313	CbGeAlD
Sorafenib—KDR—renal system—uterine cancer	0.000413	0.00312	CbGeAlD
Sorafenib—STK10—uterus—uterine cancer	0.000412	0.00311	CbGeAlD
Sorafenib—MKNK2—vagina—uterine cancer	0.000411	0.00311	CbGeAlD
Sorafenib—RALBP1—female reproductive system—uterine cancer	0.000411	0.00311	CbGeAlD
Sorafenib—CSF1R—decidua—uterine cancer	0.00041	0.0031	CbGeAlD
Sorafenib—MKNK1—female gonad—uterine cancer	0.000409	0.00309	CbGeAlD
Sorafenib—PDGFRA—uterus—uterine cancer	0.000407	0.00308	CbGeAlD
Sorafenib—MKNK1—vagina—uterine cancer	0.000406	0.00307	CbGeAlD
Sorafenib—KDR—endometrium—uterine cancer	0.000399	0.00301	CbGeAlD
Sorafenib—MAP2K5—endometrium—uterine cancer	0.000399	0.00301	CbGeAlD
Sorafenib—KIT—epithelium—uterine cancer	0.000394	0.00298	CbGeAlD
Sorafenib—FLT1—female reproductive system—uterine cancer	0.000391	0.00295	CbGeAlD
Sorafenib—KIT—uterine cervix—uterine cancer	0.000391	0.00295	CbGeAlD
Sorafenib—CSF1R—endometrium—uterine cancer	0.000389	0.00294	CbGeAlD
Sorafenib—ZAK—lymph node—uterine cancer	0.000389	0.00294	CbGeAlD
Sorafenib—RAF1—female reproductive system—uterine cancer	0.000389	0.00294	CbGeAlD
Sorafenib—HTR2B—myometrium—uterine cancer	0.000388	0.00294	CbGeAlD
Sorafenib—MAP2K5—mammalian vulva—uterine cancer	0.000386	0.00292	CbGeAlD
Sorafenib—KDR—mammalian vulva—uterine cancer	0.000386	0.00292	CbGeAlD
Sorafenib—PDGFRB—epithelium—uterine cancer	0.000385	0.00291	CbGeAlD
Sorafenib—PDGFRB—uterine cervix—uterine cancer	0.000382	0.00288	CbGeAlD
Sorafenib—HIPK3—lymph node—uterine cancer	0.000381	0.00288	CbGeAlD
Sorafenib—KIT—smooth muscle tissue—uterine cancer	0.00038	0.00287	CbGeAlD
Sorafenib—CSF1R—mammalian vulva—uterine cancer	0.000376	0.00285	CbGeAlD
Sorafenib—RALBP1—female gonad—uterine cancer	0.000374	0.00283	CbGeAlD
Sorafenib—KIT—decidua—uterine cancer	0.000372	0.00281	CbGeAlD
Sorafenib—RALBP1—vagina—uterine cancer	0.000372	0.00281	CbGeAlD
Sorafenib—PDGFRB—smooth muscle tissue—uterine cancer	0.000371	0.0028	CbGeAlD
Sorafenib—STK10—female reproductive system—uterine cancer	0.00037	0.0028	CbGeAlD
Sorafenib—KDR—uterus—uterine cancer	0.000368	0.00278	CbGeAlD
Sorafenib—PDGFRA—female reproductive system—uterine cancer	0.000366	0.00277	CbGeAlD
Sorafenib—KIT—renal system—uterine cancer	0.000366	0.00276	CbGeAlD
Sorafenib—PDGFRB—decidua—uterine cancer	0.000364	0.00275	CbGeAlD
Sorafenib—CSF1R—uterus—uterine cancer	0.000359	0.00271	CbGeAlD
Sorafenib—PDGFRB—renal system—uterine cancer	0.000357	0.0027	CbGeAlD
Sorafenib—TIE1—lymph node—uterine cancer	0.000356	0.00269	CbGeAlD
Sorafenib—FLT1—female gonad—uterine cancer	0.000356	0.00269	CbGeAlD
Sorafenib—RAF1—female gonad—uterine cancer	0.000354	0.00267	CbGeAlD
Sorafenib—FLT1—vagina—uterine cancer	0.000353	0.00267	CbGeAlD
Sorafenib—KIT—endometrium—uterine cancer	0.000353	0.00267	CbGeAlD
Sorafenib—EPHB6—female gonad—uterine cancer	0.000352	0.00266	CbGeAlD
Sorafenib—RAF1—vagina—uterine cancer	0.000351	0.00266	CbGeAlD
Sorafenib—EPHB6—vagina—uterine cancer	0.000349	0.00264	CbGeAlD
Sorafenib—PDGFRB—endometrium—uterine cancer	0.000345	0.00261	CbGeAlD
Sorafenib—KIT—mammalian vulva—uterine cancer	0.000342	0.00258	CbGeAlD
Sorafenib—BRAF—lymph node—uterine cancer	0.000341	0.00258	CbGeAlD
Sorafenib—STK10—female gonad—uterine cancer	0.000337	0.00254	CbGeAlD
Sorafenib—STK10—vagina—uterine cancer	0.000335	0.00253	CbGeAlD
Sorafenib—PDGFRB—mammalian vulva—uterine cancer	0.000334	0.00252	CbGeAlD
Sorafenib—PDGFRA—female gonad—uterine cancer	0.000333	0.00252	CbGeAlD
Sorafenib—PDGFRA—vagina—uterine cancer	0.000331	0.0025	CbGeAlD
Sorafenib—KDR—female reproductive system—uterine cancer	0.00033	0.0025	CbGeAlD
Sorafenib—MAP2K5—female reproductive system—uterine cancer	0.00033	0.0025	CbGeAlD
Sorafenib—EPHX2—lymph node—uterine cancer	0.000326	0.00246	CbGeAlD
Sorafenib—KIT—uterus—uterine cancer	0.000326	0.00246	CbGeAlD
Sorafenib—FLT3—lymph node—uterine cancer	0.000324	0.00245	CbGeAlD
Sorafenib—CSF1R—female reproductive system—uterine cancer	0.000322	0.00244	CbGeAlD
Sorafenib—PDGFRB—uterus—uterine cancer	0.000318	0.0024	CbGeAlD
Sorafenib—HTR2B—uterine cervix—uterine cancer	0.000302	0.00228	CbGeAlD
Sorafenib—KDR—female gonad—uterine cancer	0.000301	0.00227	CbGeAlD
Sorafenib—MAP2K5—female gonad—uterine cancer	0.000301	0.00227	CbGeAlD
Sorafenib—KDR—vagina—uterine cancer	0.000299	0.00226	CbGeAlD
Sorafenib—MAP2K5—vagina—uterine cancer	0.000299	0.00226	CbGeAlD
Sorafenib—FLT4—lymph node—uterine cancer	0.000294	0.00222	CbGeAlD
Sorafenib—HTR2B—smooth muscle tissue—uterine cancer	0.000294	0.00222	CbGeAlD
Sorafenib—CSF1R—female gonad—uterine cancer	0.000293	0.00222	CbGeAlD
Sorafenib—KIT—female reproductive system—uterine cancer	0.000293	0.00221	CbGeAlD
Sorafenib—CSF1R—vagina—uterine cancer	0.000292	0.0022	CbGeAlD
Sorafenib—FGFR1—lymph node—uterine cancer	0.00029	0.00219	CbGeAlD
Sorafenib—HTR2B—decidua—uterine cancer	0.000288	0.00218	CbGeAlD
Sorafenib—PDGFRB—female reproductive system—uterine cancer	0.000286	0.00216	CbGeAlD
Sorafenib—ABCC4—renal system—uterine cancer	0.000284	0.00215	CbGeAlD
Sorafenib—ABCG2—myometrium—uterine cancer	0.000276	0.00208	CbGeAlD
Sorafenib—ABCC2—renal system—uterine cancer	0.000275	0.00208	CbGeAlD
Sorafenib—MAP3K7—lymph node—uterine cancer	0.000275	0.00208	CbGeAlD
Sorafenib—HTR2B—endometrium—uterine cancer	0.000273	0.00207	CbGeAlD
Sorafenib—KIT—female gonad—uterine cancer	0.000266	0.00201	CbGeAlD
Sorafenib—MKNK2—lymph node—uterine cancer	0.000266	0.00201	CbGeAlD
Sorafenib—KIT—vagina—uterine cancer	0.000265	0.002	CbGeAlD
Sorafenib—MKNK1—lymph node—uterine cancer	0.000263	0.00199	CbGeAlD
Sorafenib—PDGFRB—female gonad—uterine cancer	0.00026	0.00197	CbGeAlD
Sorafenib—RET—lymph node—uterine cancer	0.00026	0.00196	CbGeAlD
Sorafenib—PDGFRB—vagina—uterine cancer	0.000259	0.00195	CbGeAlD
Sorafenib—ABCC4—uterus—uterine cancer	0.000253	0.00191	CbGeAlD
Sorafenib—HTR2B—uterus—uterine cancer	0.000252	0.0019	CbGeAlD
Sorafenib—HTR2C—female reproductive system—uterine cancer	0.000241	0.00182	CbGeAlD
Sorafenib—RALBP1—lymph node—uterine cancer	0.00024	0.00182	CbGeAlD
Sorafenib—FLT1—lymph node—uterine cancer	0.000229	0.00173	CbGeAlD
Sorafenib—ABCC4—female reproductive system—uterine cancer	0.000228	0.00172	CbGeAlD
Sorafenib—RAF1—lymph node—uterine cancer	0.000227	0.00172	CbGeAlD
Sorafenib—HTR2B—female reproductive system—uterine cancer	0.000226	0.00171	CbGeAlD
Sorafenib—EPHB6—lymph node—uterine cancer	0.000226	0.00171	CbGeAlD
Sorafenib—ABCC2—female reproductive system—uterine cancer	0.00022	0.00167	CbGeAlD
Sorafenib—STK10—lymph node—uterine cancer	0.000216	0.00164	CbGeAlD
Sorafenib—ABCG2—uterine cervix—uterine cancer	0.000215	0.00162	CbGeAlD
Sorafenib—PDGFRA—lymph node—uterine cancer	0.000214	0.00162	CbGeAlD
Sorafenib—ABCC4—female gonad—uterine cancer	0.000207	0.00157	CbGeAlD
Sorafenib—CYP2C8—renal system—uterine cancer	0.000206	0.00156	CbGeAlD
Sorafenib—HTR2B—vagina—uterine cancer	0.000205	0.00155	CbGeAlD
Sorafenib—ABCG2—decidua—uterine cancer	0.000204	0.00154	CbGeAlD
Sorafenib—CYP2C8—endometrium—uterine cancer	0.0002	0.00151	CbGeAlD
Sorafenib—CYP3A5—uterine cervix—uterine cancer	0.000199	0.00151	CbGeAlD
Sorafenib—ABCG2—endometrium—uterine cancer	0.000194	0.00147	CbGeAlD
Sorafenib—MAP2K5—lymph node—uterine cancer	0.000193	0.00146	CbGeAlD
Sorafenib—KDR—lymph node—uterine cancer	0.000193	0.00146	CbGeAlD
Sorafenib—CYP1A2—renal system—uterine cancer	0.000193	0.00146	CbGeAlD
Sorafenib—CSF1R—lymph node—uterine cancer	0.000189	0.00143	CbGeAlD
Sorafenib—ABCG2—mammalian vulva—uterine cancer	0.000188	0.00142	CbGeAlD
Sorafenib—CYP3A5—renal system—uterine cancer	0.000186	0.00141	CbGeAlD
Sorafenib—CYP2B6—renal system—uterine cancer	0.000185	0.0014	CbGeAlD
Sorafenib—ABCG2—uterus—uterine cancer	0.000179	0.00135	CbGeAlD
Sorafenib—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.000178	0.00109	CcSEcCtD
Sorafenib—Hepatic function abnormal—Epirubicin—uterine cancer	0.000178	0.00109	CcSEcCtD
Sorafenib—Dizziness—Progesterone—uterine cancer	0.000176	0.00108	CcSEcCtD
Sorafenib—Angiopathy—Etoposide—uterine cancer	0.000174	0.00107	CcSEcCtD
Sorafenib—Immune system disorder—Etoposide—uterine cancer	0.000173	0.00106	CcSEcCtD
Sorafenib—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000173	0.00106	CcSEcCtD
Sorafenib—Eczema—Epirubicin—uterine cancer	0.000173	0.00106	CcSEcCtD
Sorafenib—Hepatic failure—Epirubicin—uterine cancer	0.000173	0.00106	CcSEcCtD
Sorafenib—Mediastinal disorder—Etoposide—uterine cancer	0.000173	0.00106	CcSEcCtD
Sorafenib—CYP2C19—vagina—uterine cancer	0.000171	0.00129	CbGeAlD
Sorafenib—KIT—lymph node—uterine cancer	0.000171	0.00129	CbGeAlD
Sorafenib—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.000171	0.00105	CcSEcCtD
Sorafenib—Cardiac failure congestive—Epirubicin—uterine cancer	0.000171	0.00105	CcSEcCtD
Sorafenib—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.00017	0.00105	CcSEcCtD
Sorafenib—Alopecia—Etoposide—uterine cancer	0.000169	0.00104	CcSEcCtD
Sorafenib—Vomiting—Progesterone—uterine cancer	0.000169	0.00104	CcSEcCtD
Sorafenib—Renal failure acute—Epirubicin—uterine cancer	0.000168	0.00103	CcSEcCtD
Sorafenib—Rash—Progesterone—uterine cancer	0.000168	0.00103	CcSEcCtD
Sorafenib—Dermatitis—Progesterone—uterine cancer	0.000167	0.00103	CcSEcCtD
Sorafenib—PDGFRB—lymph node—uterine cancer	0.000167	0.00126	CbGeAlD
Sorafenib—Headache—Progesterone—uterine cancer	0.000167	0.00102	CcSEcCtD
Sorafenib—CYP2C8—female reproductive system—uterine cancer	0.000165	0.00125	CbGeAlD
Sorafenib—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000165	0.00101	CcSEcCtD
Sorafenib—Dermatitis exfoliative—Epirubicin—uterine cancer	0.000164	0.00101	CcSEcCtD
Sorafenib—Hepatic function abnormal—Doxorubicin—uterine cancer	0.000164	0.00101	CcSEcCtD
Sorafenib—Decreased appetite—Dactinomycin—uterine cancer	0.000163	0.001	CcSEcCtD
Sorafenib—Dysgeusia—Etoposide—uterine cancer	0.000163	0.001	CcSEcCtD
Sorafenib—Fatigue—Dactinomycin—uterine cancer	0.000162	0.000995	CcSEcCtD
Sorafenib—Pain—Dactinomycin—uterine cancer	0.000161	0.000987	CcSEcCtD
Sorafenib—Muscle spasms—Etoposide—uterine cancer	0.00016	0.000984	CcSEcCtD
Sorafenib—Hepatic failure—Doxorubicin—uterine cancer	0.00016	0.000981	CcSEcCtD
Sorafenib—Eczema—Doxorubicin—uterine cancer	0.00016	0.000981	CcSEcCtD
Sorafenib—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000159	0.000978	CcSEcCtD
Sorafenib—Cardiac failure—Epirubicin—uterine cancer	0.000159	0.000976	CcSEcCtD
Sorafenib—Cardiac failure congestive—Doxorubicin—uterine cancer	0.000158	0.000972	CcSEcCtD
Sorafenib—Nausea—Progesterone—uterine cancer	0.000158	0.00097	CcSEcCtD
Sorafenib—Hyponatraemia—Epirubicin—uterine cancer	0.000156	0.000956	CcSEcCtD
Sorafenib—Renal failure acute—Doxorubicin—uterine cancer	0.000155	0.000954	CcSEcCtD
Sorafenib—Pain in extremity—Epirubicin—uterine cancer	0.000155	0.000952	CcSEcCtD
Sorafenib—Anaemia—Etoposide—uterine cancer	0.000154	0.000946	CcSEcCtD
Sorafenib—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000154	0.000943	CcSEcCtD
Sorafenib—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000153	0.00094	CcSEcCtD
Sorafenib—Dermatitis exfoliative—Doxorubicin—uterine cancer	0.000152	0.000934	CcSEcCtD
Sorafenib—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000152	0.000933	CcSEcCtD
Sorafenib—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000152	0.000932	CcSEcCtD
Sorafenib—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000151	0.000927	CcSEcCtD
Sorafenib—CYP2C8—vagina—uterine cancer	0.000149	0.00113	CbGeAlD
Sorafenib—Leukopenia—Etoposide—uterine cancer	0.000149	0.000916	CcSEcCtD
Sorafenib—Body temperature increased—Dactinomycin—uterine cancer	0.000149	0.000912	CcSEcCtD
Sorafenib—Abdominal pain—Dactinomycin—uterine cancer	0.000149	0.000912	CcSEcCtD
Sorafenib—CYP2B6—female reproductive system—uterine cancer	0.000148	0.00112	CbGeAlD
Sorafenib—Cardiac failure—Doxorubicin—uterine cancer	0.000147	0.000903	CcSEcCtD
Sorafenib—Mood swings—Epirubicin—uterine cancer	0.000147	0.000902	CcSEcCtD
Sorafenib—CYP2C9—female reproductive system—uterine cancer	0.000147	0.00111	CbGeAlD
Sorafenib—Loss of consciousness—Etoposide—uterine cancer	0.000146	0.000899	CcSEcCtD
Sorafenib—ABCG2—female gonad—uterine cancer	0.000146	0.00111	CbGeAlD
Sorafenib—Cough—Etoposide—uterine cancer	0.000145	0.000893	CcSEcCtD
Sorafenib—ABCG2—vagina—uterine cancer	0.000145	0.0011	CbGeAlD
Sorafenib—Dehydration—Epirubicin—uterine cancer	0.000144	0.000886	CcSEcCtD
Sorafenib—Hyponatraemia—Doxorubicin—uterine cancer	0.000144	0.000885	CcSEcCtD
Sorafenib—Hypertension—Etoposide—uterine cancer	0.000144	0.000883	CcSEcCtD
Sorafenib—Pain in extremity—Doxorubicin—uterine cancer	0.000144	0.000881	CcSEcCtD
Sorafenib—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000143	0.000879	CcSEcCtD
Sorafenib—Dry skin—Epirubicin—uterine cancer	0.000142	0.000873	CcSEcCtD
Sorafenib—Abdominal pain upper—Epirubicin—uterine cancer	0.000142	0.00087	CcSEcCtD
Sorafenib—Hypokalaemia—Epirubicin—uterine cancer	0.000141	0.000867	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000141	0.000865	CcSEcCtD
Sorafenib—Breast disorder—Epirubicin—uterine cancer	0.00014	0.000861	CcSEcCtD
Sorafenib—CYP3A4—renal system—uterine cancer	0.00014	0.00106	CbGeAlD
Sorafenib—Aspartate aminotransferase increased—Epirubicin—uterine cancer	0.00014	0.000858	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Epirubicin—uterine cancer	0.00014	0.000858	CcSEcCtD
Sorafenib—Nasopharyngitis—Epirubicin—uterine cancer	0.000139	0.000852	CcSEcCtD
Sorafenib—Hypersensitivity—Dactinomycin—uterine cancer	0.000138	0.00085	CcSEcCtD
Sorafenib—CYP2D6—renal system—uterine cancer	0.000138	0.00104	CbGeAlD
Sorafenib—Gastritis—Epirubicin—uterine cancer	0.000137	0.000843	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Epirubicin—uterine cancer	0.000137	0.00084	CcSEcCtD
Sorafenib—Anaphylactic shock—Etoposide—uterine cancer	0.000136	0.000835	CcSEcCtD
Sorafenib—Mood swings—Doxorubicin—uterine cancer	0.000136	0.000835	CcSEcCtD
Sorafenib—ABCB1—myometrium—uterine cancer	0.000136	0.00103	CbGeAlD
Sorafenib—CYP3A5—female gonad—uterine cancer	0.000136	0.00103	CbGeAlD
Sorafenib—Infection—Etoposide—uterine cancer	0.000135	0.00083	CcSEcCtD
Sorafenib—CYP3A5—vagina—uterine cancer	0.000135	0.00102	CbGeAlD
Sorafenib—Asthenia—Dactinomycin—uterine cancer	0.000135	0.000828	CcSEcCtD
Sorafenib—CYP2B6—vagina—uterine cancer	0.000134	0.00101	CbGeAlD
Sorafenib—Dysphagia—Epirubicin—uterine cancer	0.000134	0.000823	CcSEcCtD
Sorafenib—Dehydration—Doxorubicin—uterine cancer	0.000133	0.00082	CcSEcCtD
Sorafenib—ABCC4—lymph node—uterine cancer	0.000133	0.00101	CbGeAlD
Sorafenib—Thrombocytopenia—Etoposide—uterine cancer	0.000133	0.000818	CcSEcCtD
Sorafenib—HTR2B—lymph node—uterine cancer	0.000132	0.001	CbGeAlD
Sorafenib—Skin disorder—Etoposide—uterine cancer	0.000132	0.000811	CcSEcCtD
Sorafenib—Dry skin—Doxorubicin—uterine cancer	0.000132	0.000808	CcSEcCtD
Sorafenib—Pancreatitis—Epirubicin—uterine cancer	0.000131	0.000807	CcSEcCtD
Sorafenib—Abdominal pain upper—Doxorubicin—uterine cancer	0.000131	0.000805	CcSEcCtD
Sorafenib—Hypokalaemia—Doxorubicin—uterine cancer	0.000131	0.000802	CcSEcCtD
Sorafenib—Breast disorder—Doxorubicin—uterine cancer	0.00013	0.000796	CcSEcCtD
Sorafenib—Anorexia—Etoposide—uterine cancer	0.00013	0.000796	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	0.000129	0.000794	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Doxorubicin—uterine cancer	0.000129	0.000794	CcSEcCtD
Sorafenib—ABCC2—lymph node—uterine cancer	0.000129	0.000975	CbGeAlD
Sorafenib—Diarrhoea—Dactinomycin—uterine cancer	0.000129	0.000789	CcSEcCtD
Sorafenib—Nasopharyngitis—Doxorubicin—uterine cancer	0.000128	0.000788	CcSEcCtD
Sorafenib—Gastritis—Doxorubicin—uterine cancer	0.000127	0.00078	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000127	0.000777	CcSEcCtD
Sorafenib—Neutropenia—Epirubicin—uterine cancer	0.000125	0.00077	CcSEcCtD
Sorafenib—Dysphagia—Doxorubicin—uterine cancer	0.000124	0.000762	CcSEcCtD
Sorafenib—Pancreatitis—Doxorubicin—uterine cancer	0.000122	0.000747	CcSEcCtD
Sorafenib—Weight decreased—Epirubicin—uterine cancer	0.000121	0.000745	CcSEcCtD
Sorafenib—Dyspnoea—Etoposide—uterine cancer	0.000121	0.000744	CcSEcCtD
Sorafenib—Pneumonia—Epirubicin—uterine cancer	0.00012	0.000738	CcSEcCtD
Sorafenib—Infestation—Epirubicin—uterine cancer	0.00012	0.000734	CcSEcCtD
Sorafenib—Infestation NOS—Epirubicin—uterine cancer	0.00012	0.000734	CcSEcCtD
Sorafenib—Vomiting—Dactinomycin—uterine cancer	0.000119	0.000734	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Epirubicin—uterine cancer	0.000119	0.000728	CcSEcCtD
Sorafenib—Rash—Dactinomycin—uterine cancer	0.000118	0.000727	CcSEcCtD
Sorafenib—Decreased appetite—Etoposide—uterine cancer	0.000118	0.000726	CcSEcCtD
Sorafenib—Renal failure—Epirubicin—uterine cancer	0.000118	0.000721	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Etoposide—uterine cancer	0.000117	0.000721	CcSEcCtD
Sorafenib—Fatigue—Etoposide—uterine cancer	0.000117	0.00072	CcSEcCtD
Sorafenib—Neuropathy peripheral—Epirubicin—uterine cancer	0.000117	0.000719	CcSEcCtD
Sorafenib—Stomatitis—Epirubicin—uterine cancer	0.000117	0.000715	CcSEcCtD
Sorafenib—Jaundice—Epirubicin—uterine cancer	0.000117	0.000715	CcSEcCtD
Sorafenib—Constipation—Etoposide—uterine cancer	0.000116	0.000714	CcSEcCtD
Sorafenib—Pain—Etoposide—uterine cancer	0.000116	0.000714	CcSEcCtD
Sorafenib—Neutropenia—Doxorubicin—uterine cancer	0.000116	0.000712	CcSEcCtD
Sorafenib—Hepatobiliary disease—Epirubicin—uterine cancer	0.000113	0.000694	CcSEcCtD
Sorafenib—Epistaxis—Epirubicin—uterine cancer	0.000113	0.000692	CcSEcCtD
Sorafenib—Weight decreased—Doxorubicin—uterine cancer	0.000112	0.000689	CcSEcCtD
Sorafenib—CYP3A4—female reproductive system—uterine cancer	0.000112	0.000846	CbGeAlD
Sorafenib—Nausea—Dactinomycin—uterine cancer	0.000112	0.000685	CcSEcCtD
Sorafenib—Pneumonia—Doxorubicin—uterine cancer	0.000111	0.000683	CcSEcCtD
Sorafenib—Gastrointestinal pain—Etoposide—uterine cancer	0.000111	0.000683	CcSEcCtD
Sorafenib—Infestation NOS—Doxorubicin—uterine cancer	0.000111	0.000679	CcSEcCtD
Sorafenib—Infestation—Doxorubicin—uterine cancer	0.000111	0.000679	CcSEcCtD
Sorafenib—CYP2D6—female reproductive system—uterine cancer	0.00011	0.000833	CbGeAlD
Sorafenib—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	0.00011	0.000673	CcSEcCtD
Sorafenib—Renal failure—Doxorubicin—uterine cancer	0.000109	0.000668	CcSEcCtD
Sorafenib—Neuropathy peripheral—Doxorubicin—uterine cancer	0.000108	0.000666	CcSEcCtD
Sorafenib—Urticaria—Etoposide—uterine cancer	0.000108	0.000663	CcSEcCtD
Sorafenib—Haemoglobin—Epirubicin—uterine cancer	0.000108	0.000662	CcSEcCtD
Sorafenib—Stomatitis—Doxorubicin—uterine cancer	0.000108	0.000662	CcSEcCtD
Sorafenib—Jaundice—Doxorubicin—uterine cancer	0.000108	0.000662	CcSEcCtD
Sorafenib—Body temperature increased—Etoposide—uterine cancer	0.000108	0.00066	CcSEcCtD
Sorafenib—Abdominal pain—Etoposide—uterine cancer	0.000108	0.00066	CcSEcCtD
Sorafenib—Haemorrhage—Epirubicin—uterine cancer	0.000107	0.000659	CcSEcCtD
Sorafenib—ABCB1—epithelium—uterine cancer	0.000107	0.000806	CbGeAlD
Sorafenib—Urinary tract disorder—Epirubicin—uterine cancer	0.000106	0.000651	CcSEcCtD
Sorafenib—ABCB1—uterine cervix—uterine cancer	0.000106	0.0008	CbGeAlD
Sorafenib—Connective tissue disorder—Epirubicin—uterine cancer	0.000105	0.000647	CcSEcCtD
Sorafenib—Urethral disorder—Epirubicin—uterine cancer	0.000105	0.000646	CcSEcCtD
Sorafenib—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000105	0.000642	CcSEcCtD
Sorafenib—Epistaxis—Doxorubicin—uterine cancer	0.000104	0.000641	CcSEcCtD
Sorafenib—Erythema multiforme—Epirubicin—uterine cancer	0.000101	0.000623	CcSEcCtD
Sorafenib—ABCB1—decidua—uterine cancer	0.000101	0.000762	CbGeAlD
Sorafenib—CYP2D6—female gonad—uterine cancer	0.0001	0.000758	CbGeAlD
Sorafenib—Hypersensitivity—Etoposide—uterine cancer	0.0001	0.000615	CcSEcCtD
Sorafenib—Tinnitus—Epirubicin—uterine cancer	0.0001	0.000614	CcSEcCtD
Sorafenib—Haemoglobin—Doxorubicin—uterine cancer	9.98e-05	0.000613	CcSEcCtD
Sorafenib—Flushing—Epirubicin—uterine cancer	9.96e-05	0.000611	CcSEcCtD
Sorafenib—Cardiac disorder—Epirubicin—uterine cancer	9.96e-05	0.000611	CcSEcCtD
Sorafenib—Haemorrhage—Doxorubicin—uterine cancer	9.93e-05	0.00061	CcSEcCtD
Sorafenib—ABCB1—renal system—uterine cancer	9.9e-05	0.000748	CbGeAlD
Sorafenib—Urinary tract disorder—Doxorubicin—uterine cancer	9.81e-05	0.000602	CcSEcCtD
Sorafenib—Asthenia—Etoposide—uterine cancer	9.76e-05	0.000599	CcSEcCtD
Sorafenib—Connective tissue disorder—Doxorubicin—uterine cancer	9.76e-05	0.000599	CcSEcCtD
Sorafenib—Angiopathy—Epirubicin—uterine cancer	9.74e-05	0.000598	CcSEcCtD
Sorafenib—Urethral disorder—Doxorubicin—uterine cancer	9.73e-05	0.000598	CcSEcCtD
Sorafenib—Immune system disorder—Epirubicin—uterine cancer	9.69e-05	0.000595	CcSEcCtD
Sorafenib—Mediastinal disorder—Epirubicin—uterine cancer	9.67e-05	0.000594	CcSEcCtD
Sorafenib—Pruritus—Etoposide—uterine cancer	9.62e-05	0.000591	CcSEcCtD
Sorafenib—Arrhythmia—Epirubicin—uterine cancer	9.59e-05	0.000589	CcSEcCtD
Sorafenib—ABCB1—endometrium—uterine cancer	9.57e-05	0.000723	CbGeAlD
Sorafenib—Alopecia—Epirubicin—uterine cancer	9.48e-05	0.000582	CcSEcCtD
Sorafenib—ABCG2—lymph node—uterine cancer	9.4e-05	0.000711	CbGeAlD
Sorafenib—Mental disorder—Epirubicin—uterine cancer	9.4e-05	0.000577	CcSEcCtD
Sorafenib—Erythema multiforme—Doxorubicin—uterine cancer	9.39e-05	0.000576	CcSEcCtD
Sorafenib—Erythema—Epirubicin—uterine cancer	9.34e-05	0.000574	CcSEcCtD
Sorafenib—Malnutrition—Epirubicin—uterine cancer	9.34e-05	0.000574	CcSEcCtD
Sorafenib—Diarrhoea—Etoposide—uterine cancer	9.31e-05	0.000571	CcSEcCtD
Sorafenib—Tinnitus—Doxorubicin—uterine cancer	9.26e-05	0.000568	CcSEcCtD
Sorafenib—ABCB1—mammalian vulva—uterine cancer	9.25e-05	0.0007	CbGeAlD
Sorafenib—Flushing—Doxorubicin—uterine cancer	9.22e-05	0.000566	CcSEcCtD
Sorafenib—Cardiac disorder—Doxorubicin—uterine cancer	9.22e-05	0.000566	CcSEcCtD
Sorafenib—Dysgeusia—Epirubicin—uterine cancer	9.15e-05	0.000562	CcSEcCtD
Sorafenib—Angiopathy—Doxorubicin—uterine cancer	9.01e-05	0.000553	CcSEcCtD
Sorafenib—Dizziness—Etoposide—uterine cancer	8.99e-05	0.000552	CcSEcCtD
Sorafenib—Muscle spasms—Epirubicin—uterine cancer	8.98e-05	0.000551	CcSEcCtD
Sorafenib—Immune system disorder—Doxorubicin—uterine cancer	8.97e-05	0.000551	CcSEcCtD
Sorafenib—Mediastinal disorder—Doxorubicin—uterine cancer	8.95e-05	0.000549	CcSEcCtD
Sorafenib—Arrhythmia—Doxorubicin—uterine cancer	8.87e-05	0.000545	CcSEcCtD
Sorafenib—ABCB1—uterus—uterine cancer	8.82e-05	0.000666	CbGeAlD
Sorafenib—Alopecia—Doxorubicin—uterine cancer	8.77e-05	0.000539	CcSEcCtD
Sorafenib—Mental disorder—Doxorubicin—uterine cancer	8.7e-05	0.000534	CcSEcCtD
Sorafenib—Vomiting—Etoposide—uterine cancer	8.65e-05	0.000531	CcSEcCtD
Sorafenib—Malnutrition—Doxorubicin—uterine cancer	8.64e-05	0.000531	CcSEcCtD
Sorafenib—Erythema—Doxorubicin—uterine cancer	8.64e-05	0.000531	CcSEcCtD
Sorafenib—Anaemia—Epirubicin—uterine cancer	8.63e-05	0.00053	CcSEcCtD
Sorafenib—Rash—Etoposide—uterine cancer	8.58e-05	0.000527	CcSEcCtD
Sorafenib—Dermatitis—Etoposide—uterine cancer	8.57e-05	0.000526	CcSEcCtD
Sorafenib—Headache—Etoposide—uterine cancer	8.52e-05	0.000523	CcSEcCtD
Sorafenib—Dysgeusia—Doxorubicin—uterine cancer	8.46e-05	0.00052	CcSEcCtD
Sorafenib—Syncope—Epirubicin—uterine cancer	8.38e-05	0.000514	CcSEcCtD
Sorafenib—Leukopenia—Epirubicin—uterine cancer	8.36e-05	0.000513	CcSEcCtD
Sorafenib—Muscle spasms—Doxorubicin—uterine cancer	8.31e-05	0.00051	CcSEcCtD
Sorafenib—Loss of consciousness—Epirubicin—uterine cancer	8.21e-05	0.000504	CcSEcCtD
Sorafenib—Cough—Epirubicin—uterine cancer	8.15e-05	0.0005	CcSEcCtD
Sorafenib—Nausea—Etoposide—uterine cancer	8.08e-05	0.000496	CcSEcCtD
Sorafenib—Hypertension—Epirubicin—uterine cancer	8.07e-05	0.000495	CcSEcCtD
Sorafenib—Anaemia—Doxorubicin—uterine cancer	7.99e-05	0.00049	CcSEcCtD
Sorafenib—Arthralgia—Epirubicin—uterine cancer	7.95e-05	0.000488	CcSEcCtD
Sorafenib—Myalgia—Epirubicin—uterine cancer	7.95e-05	0.000488	CcSEcCtD
Sorafenib—ABCB1—female reproductive system—uterine cancer	7.93e-05	0.000599	CbGeAlD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	7.9e-05	0.000485	CcSEcCtD
Sorafenib—Dry mouth—Epirubicin—uterine cancer	7.78e-05	0.000478	CcSEcCtD
Sorafenib—Syncope—Doxorubicin—uterine cancer	7.75e-05	0.000476	CcSEcCtD
Sorafenib—Leukopenia—Doxorubicin—uterine cancer	7.74e-05	0.000475	CcSEcCtD
Sorafenib—Anaphylactic shock—Epirubicin—uterine cancer	7.62e-05	0.000468	CcSEcCtD
Sorafenib—Loss of consciousness—Doxorubicin—uterine cancer	7.6e-05	0.000466	CcSEcCtD
Sorafenib—Infection—Epirubicin—uterine cancer	7.57e-05	0.000465	CcSEcCtD
Sorafenib—Cough—Doxorubicin—uterine cancer	7.54e-05	0.000463	CcSEcCtD
Sorafenib—Shock—Epirubicin—uterine cancer	7.5e-05	0.000461	CcSEcCtD
Sorafenib—Nervous system disorder—Epirubicin—uterine cancer	7.48e-05	0.000459	CcSEcCtD
Sorafenib—Thrombocytopenia—Epirubicin—uterine cancer	7.46e-05	0.000458	CcSEcCtD
Sorafenib—Hypertension—Doxorubicin—uterine cancer	7.46e-05	0.000458	CcSEcCtD
Sorafenib—Skin disorder—Epirubicin—uterine cancer	7.41e-05	0.000455	CcSEcCtD
Sorafenib—Arthralgia—Doxorubicin—uterine cancer	7.36e-05	0.000452	CcSEcCtD
Sorafenib—Myalgia—Doxorubicin—uterine cancer	7.36e-05	0.000452	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	7.31e-05	0.000449	CcSEcCtD
Sorafenib—Anorexia—Epirubicin—uterine cancer	7.27e-05	0.000446	CcSEcCtD
Sorafenib—ABCB1—female gonad—uterine cancer	7.21e-05	0.000545	CbGeAlD
Sorafenib—Dry mouth—Doxorubicin—uterine cancer	7.2e-05	0.000442	CcSEcCtD
Sorafenib—ABCB1—vagina—uterine cancer	7.17e-05	0.000542	CbGeAlD
Sorafenib—Anaphylactic shock—Doxorubicin—uterine cancer	7.05e-05	0.000433	CcSEcCtD
Sorafenib—Infection—Doxorubicin—uterine cancer	7.01e-05	0.00043	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Epirubicin—uterine cancer	6.95e-05	0.000426	CcSEcCtD
Sorafenib—Shock—Doxorubicin—uterine cancer	6.94e-05	0.000426	CcSEcCtD
Sorafenib—Nervous system disorder—Doxorubicin—uterine cancer	6.92e-05	0.000425	CcSEcCtD
Sorafenib—Thrombocytopenia—Doxorubicin—uterine cancer	6.91e-05	0.000424	CcSEcCtD
Sorafenib—Skin disorder—Doxorubicin—uterine cancer	6.85e-05	0.000421	CcSEcCtD
Sorafenib—Dyspnoea—Epirubicin—uterine cancer	6.8e-05	0.000417	CcSEcCtD
Sorafenib—Anorexia—Doxorubicin—uterine cancer	6.72e-05	0.000413	CcSEcCtD
Sorafenib—Dyspepsia—Epirubicin—uterine cancer	6.71e-05	0.000412	CcSEcCtD
Sorafenib—Decreased appetite—Epirubicin—uterine cancer	6.63e-05	0.000407	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Epirubicin—uterine cancer	6.58e-05	0.000404	CcSEcCtD
Sorafenib—Fatigue—Epirubicin—uterine cancer	6.57e-05	0.000404	CcSEcCtD
Sorafenib—Constipation—Epirubicin—uterine cancer	6.52e-05	0.0004	CcSEcCtD
Sorafenib—Pain—Epirubicin—uterine cancer	6.52e-05	0.0004	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Doxorubicin—uterine cancer	6.43e-05	0.000395	CcSEcCtD
Sorafenib—Dyspnoea—Doxorubicin—uterine cancer	6.29e-05	0.000386	CcSEcCtD
Sorafenib—Gastrointestinal pain—Epirubicin—uterine cancer	6.23e-05	0.000383	CcSEcCtD
Sorafenib—Dyspepsia—Doxorubicin—uterine cancer	6.21e-05	0.000381	CcSEcCtD
Sorafenib—Decreased appetite—Doxorubicin—uterine cancer	6.13e-05	0.000377	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Doxorubicin—uterine cancer	6.09e-05	0.000374	CcSEcCtD
Sorafenib—Fatigue—Doxorubicin—uterine cancer	6.08e-05	0.000373	CcSEcCtD
Sorafenib—Urticaria—Epirubicin—uterine cancer	6.06e-05	0.000372	CcSEcCtD
Sorafenib—Constipation—Doxorubicin—uterine cancer	6.03e-05	0.00037	CcSEcCtD
Sorafenib—Pain—Doxorubicin—uterine cancer	6.03e-05	0.00037	CcSEcCtD
Sorafenib—Abdominal pain—Epirubicin—uterine cancer	6.03e-05	0.00037	CcSEcCtD
Sorafenib—Body temperature increased—Epirubicin—uterine cancer	6.03e-05	0.00037	CcSEcCtD
Sorafenib—Gastrointestinal pain—Doxorubicin—uterine cancer	5.77e-05	0.000354	CcSEcCtD
Sorafenib—Hypersensitivity—Epirubicin—uterine cancer	5.62e-05	0.000345	CcSEcCtD
Sorafenib—Urticaria—Doxorubicin—uterine cancer	5.6e-05	0.000344	CcSEcCtD
Sorafenib—Abdominal pain—Doxorubicin—uterine cancer	5.58e-05	0.000342	CcSEcCtD
Sorafenib—Body temperature increased—Doxorubicin—uterine cancer	5.58e-05	0.000342	CcSEcCtD
Sorafenib—Asthenia—Epirubicin—uterine cancer	5.47e-05	0.000336	CcSEcCtD
Sorafenib—Pruritus—Epirubicin—uterine cancer	5.39e-05	0.000331	CcSEcCtD
Sorafenib—Diarrhoea—Epirubicin—uterine cancer	5.22e-05	0.00032	CcSEcCtD
Sorafenib—Hypersensitivity—Doxorubicin—uterine cancer	5.2e-05	0.000319	CcSEcCtD
Sorafenib—Asthenia—Doxorubicin—uterine cancer	5.06e-05	0.000311	CcSEcCtD
Sorafenib—Dizziness—Epirubicin—uterine cancer	5.04e-05	0.00031	CcSEcCtD
Sorafenib—Pruritus—Doxorubicin—uterine cancer	4.99e-05	0.000306	CcSEcCtD
Sorafenib—Vomiting—Epirubicin—uterine cancer	4.85e-05	0.000298	CcSEcCtD
Sorafenib—Diarrhoea—Doxorubicin—uterine cancer	4.83e-05	0.000296	CcSEcCtD
Sorafenib—Rash—Epirubicin—uterine cancer	4.81e-05	0.000295	CcSEcCtD
Sorafenib—Dermatitis—Epirubicin—uterine cancer	4.8e-05	0.000295	CcSEcCtD
Sorafenib—Headache—Epirubicin—uterine cancer	4.78e-05	0.000293	CcSEcCtD
Sorafenib—Dizziness—Doxorubicin—uterine cancer	4.67e-05	0.000286	CcSEcCtD
Sorafenib—ABCB1—lymph node—uterine cancer	4.64e-05	0.00035	CbGeAlD
Sorafenib—Nausea—Epirubicin—uterine cancer	4.53e-05	0.000278	CcSEcCtD
Sorafenib—Vomiting—Doxorubicin—uterine cancer	4.49e-05	0.000275	CcSEcCtD
Sorafenib—Rash—Doxorubicin—uterine cancer	4.45e-05	0.000273	CcSEcCtD
Sorafenib—Dermatitis—Doxorubicin—uterine cancer	4.44e-05	0.000273	CcSEcCtD
Sorafenib—Headache—Doxorubicin—uterine cancer	4.42e-05	0.000271	CcSEcCtD
Sorafenib—Nausea—Doxorubicin—uterine cancer	4.19e-05	0.000257	CcSEcCtD
Sorafenib—BRAF—Disease—HRAS—uterine cancer	3.35e-06	1.99e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—MTHFR—uterine cancer	3.34e-06	1.98e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—KRAS—uterine cancer	3.32e-06	1.97e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—KRAS—uterine cancer	3.31e-06	1.97e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—HRAS—uterine cancer	3.3e-06	1.96e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—HRAS—uterine cancer	3.3e-06	1.96e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—PIK3CA—uterine cancer	3.3e-06	1.96e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—VEGFA—uterine cancer	3.28e-06	1.95e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—ERBB2—uterine cancer	3.27e-06	1.94e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—PTEN—uterine cancer	3.27e-06	1.94e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—PTEN—uterine cancer	3.27e-06	1.94e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—VEGFA—uterine cancer	3.25e-06	1.93e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—NRAS—uterine cancer	3.24e-06	1.92e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—KRAS—uterine cancer	3.24e-06	1.92e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—NRAS—uterine cancer	3.24e-06	1.92e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—AKT1—uterine cancer	3.23e-06	1.92e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—KRAS—uterine cancer	3.23e-06	1.92e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	3.23e-06	1.92e-05	CbGpPWpGaD
Sorafenib—MAPK11—Gene Expression—AKT1—uterine cancer	3.22e-06	1.91e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—NRAS—uterine cancer	3.21e-06	1.9e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CTNNB1—uterine cancer	3.19e-06	1.89e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—PIK3CA—uterine cancer	3.18e-06	1.89e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CTNNB1—uterine cancer	3.18e-06	1.89e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—NRAS—uterine cancer	3.17e-06	1.88e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—STK11—uterine cancer	3.16e-06	1.88e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CYP19A1—uterine cancer	3.16e-06	1.88e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—HRAS—uterine cancer	3.13e-06	1.86e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CYP19A1—uterine cancer	3.13e-06	1.86e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—STK11—uterine cancer	3.13e-06	1.86e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—PIK3CA—uterine cancer	3.13e-06	1.86e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—HRAS—uterine cancer	3.13e-06	1.86e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—ERBB2—uterine cancer	3.12e-06	1.85e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—EP300—uterine cancer	3.12e-06	1.85e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—EP300—uterine cancer	3.12e-06	1.85e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—PIK3CA—uterine cancer	3.12e-06	1.85e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—PTEN—uterine cancer	3.11e-06	1.84e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CXCL8—uterine cancer	3.1e-06	1.84e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—PTEN—uterine cancer	3.1e-06	1.84e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—uterine cancer	3.08e-06	1.83e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—RRM2—uterine cancer	3.07e-06	1.82e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—KRAS—uterine cancer	3.06e-06	1.82e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PTEN—uterine cancer	3.06e-06	1.81e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PTEN—uterine cancer	3.06e-06	1.81e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—PIK3CA—uterine cancer	3.05e-06	1.81e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—HRAS—uterine cancer	3.05e-06	1.81e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—PIK3CA—uterine cancer	3.04e-06	1.81e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CDKN1B—uterine cancer	3.03e-06	1.8e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCL2—uterine cancer	3.02e-06	1.79e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—DCN—uterine cancer	2.98e-06	1.77e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—PIK3CA—uterine cancer	2.98e-06	1.77e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—PIK3CA—uterine cancer	2.97e-06	1.76e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—EP300—uterine cancer	2.96e-06	1.76e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CXCL8—uterine cancer	2.96e-06	1.76e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—AKT1—uterine cancer	2.96e-06	1.76e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—VEGFA—uterine cancer	2.96e-06	1.75e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—VEGFA—uterine cancer	2.96e-06	1.75e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TP53—uterine cancer	2.96e-06	1.75e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—EP300—uterine cancer	2.95e-06	1.75e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—KRAS—uterine cancer	2.95e-06	1.75e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	2.94e-06	1.75e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—HRAS—uterine cancer	2.94e-06	1.75e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—NRAS—uterine cancer	2.92e-06	1.73e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—NRAS—uterine cancer	2.92e-06	1.73e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—AKT1—uterine cancer	2.92e-06	1.73e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—AKT1—uterine cancer	2.92e-06	1.73e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—ERBB2—uterine cancer	2.92e-06	1.73e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—EP300—uterine cancer	2.92e-06	1.73e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—EP300—uterine cancer	2.92e-06	1.73e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—HRAS—uterine cancer	2.89e-06	1.72e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—MTHFR—uterine cancer	2.89e-06	1.72e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CDKN1B—uterine cancer	2.89e-06	1.72e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—HRAS—uterine cancer	2.89e-06	1.71e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TP53—uterine cancer	2.88e-06	1.71e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CTNNB1—uterine cancer	2.86e-06	1.7e-05	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—AKT1—uterine cancer	2.86e-06	1.7e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—HRAS—uterine cancer	2.83e-06	1.68e-05	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—PIK3CA—uterine cancer	2.82e-06	1.68e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—HRAS—uterine cancer	2.82e-06	1.67e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—PIK3CA—uterine cancer	2.81e-06	1.67e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP11A1—uterine cancer	2.81e-06	1.67e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.81e-06	1.67e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—VEGFA—uterine cancer	2.8e-06	1.66e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—VEGFA—uterine cancer	2.8e-06	1.66e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—KRAS—uterine cancer	2.79e-06	1.66e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—PTEN—uterine cancer	2.79e-06	1.66e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—KRAS—uterine cancer	2.79e-06	1.65e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—NRAS—uterine cancer	2.77e-06	1.64e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—AKT1—uterine cancer	2.77e-06	1.64e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CXCL8—uterine cancer	2.77e-06	1.64e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—NRAS—uterine cancer	2.76e-06	1.64e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—AKT1—uterine cancer	2.76e-06	1.64e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—KRAS—uterine cancer	2.76e-06	1.64e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—HRAS—uterine cancer	2.75e-06	1.63e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—HRAS—uterine cancer	2.75e-06	1.63e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CTNNB1—uterine cancer	2.73e-06	1.62e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—KRAS—uterine cancer	2.73e-06	1.62e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—PIK3CA—uterine cancer	2.71e-06	1.61e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CDKN1B—uterine cancer	2.7e-06	1.6e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—AKT1—uterine cancer	2.69e-06	1.6e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—STK11—uterine cancer	2.68e-06	1.59e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CYP19A1—uterine cancer	2.68e-06	1.59e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—EP300—uterine cancer	2.66e-06	1.58e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PTEN—uterine cancer	2.66e-06	1.58e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AKR1C3—uterine cancer	2.65e-06	1.57e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—HRAS—uterine cancer	2.6e-06	1.54e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—AKT1—uterine cancer	2.6e-06	1.54e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PTEN—uterine cancer	2.59e-06	1.54e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—MTHFR—uterine cancer	2.58e-06	1.53e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PTEN—uterine cancer	2.57e-06	1.53e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—PIK3CA—uterine cancer	2.56e-06	1.52e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—PIK3CA—uterine cancer	2.56e-06	1.52e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—AKT1—uterine cancer	2.56e-06	1.52e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CTNNB1—uterine cancer	2.55e-06	1.51e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.55e-06	1.51e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—AKT1—uterine cancer	2.55e-06	1.51e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—EP300—uterine cancer	2.54e-06	1.51e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—PIK3CA—uterine cancer	2.54e-06	1.51e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—MTHFR—uterine cancer	2.52e-06	1.5e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—VEGFA—uterine cancer	2.52e-06	1.5e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—ERBB2—uterine cancer	2.52e-06	1.49e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	2.51e-06	1.49e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—KRAS—uterine cancer	2.51e-06	1.49e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—KRAS—uterine cancer	2.51e-06	1.49e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HRAS—uterine cancer	2.51e-06	1.49e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—PIK3CA—uterine cancer	2.51e-06	1.49e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—AKT1—uterine cancer	2.5e-06	1.48e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NRAS—uterine cancer	2.49e-06	1.48e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—AKT1—uterine cancer	2.49e-06	1.48e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PTEN—uterine cancer	2.49e-06	1.48e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—uterine cancer	2.48e-06	1.47e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—EP300—uterine cancer	2.47e-06	1.47e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—uterine cancer	2.45e-06	1.46e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—EP300—uterine cancer	2.45e-06	1.46e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—AKT1—uterine cancer	2.43e-06	1.44e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—AKT1—uterine cancer	2.43e-06	1.44e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—VEGFA—uterine cancer	2.4e-06	1.43e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.4e-06	1.42e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CXCL8—uterine cancer	2.39e-06	1.42e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—KRAS—uterine cancer	2.38e-06	1.42e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—KRAS—uterine cancer	2.38e-06	1.41e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—MTHFR—uterine cancer	2.38e-06	1.41e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NRAS—uterine cancer	2.37e-06	1.41e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—HRAS—uterine cancer	2.37e-06	1.41e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—EP300—uterine cancer	2.37e-06	1.41e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—HRAS—uterine cancer	2.37e-06	1.41e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—MTHFR—uterine cancer	2.36e-06	1.4e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—HRAS—uterine cancer	2.35e-06	1.39e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CDKN1B—uterine cancer	2.33e-06	1.38e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—HRAS—uterine cancer	2.32e-06	1.38e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—PIK3CA—uterine cancer	2.31e-06	1.37e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—PIK3CA—uterine cancer	2.31e-06	1.37e-05	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—AKT1—uterine cancer	2.31e-06	1.37e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—AKT1—uterine cancer	2.3e-06	1.36e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.28e-06	1.35e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—VEGFA—uterine cancer	2.25e-06	1.33e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—uterine cancer	2.23e-06	1.33e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—uterine cancer	2.23e-06	1.33e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NRAS—uterine cancer	2.22e-06	1.32e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—AKT1—uterine cancer	2.22e-06	1.32e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CTNNB1—uterine cancer	2.2e-06	1.31e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—PIK3CA—uterine cancer	2.19e-06	1.3e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—PIK3CA—uterine cancer	2.18e-06	1.3e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PIK3CA—uterine cancer	2.16e-06	1.28e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PIK3CA—uterine cancer	2.16e-06	1.28e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PTEN—uterine cancer	2.15e-06	1.27e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—KRAS—uterine cancer	2.14e-06	1.27e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—HRAS—uterine cancer	2.14e-06	1.27e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—HRAS—uterine cancer	2.14e-06	1.27e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—uterine cancer	2.12e-06	1.26e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—uterine cancer	2.11e-06	1.25e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—AKT1—uterine cancer	2.09e-06	1.24e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—AKT1—uterine cancer	2.09e-06	1.24e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.08e-06	1.23e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—AKT1—uterine cancer	2.07e-06	1.23e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—STK11—uterine cancer	2.07e-06	1.23e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CYP19A1—uterine cancer	2.07e-06	1.23e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—EP300—uterine cancer	2.05e-06	1.22e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—AKT1—uterine cancer	2.05e-06	1.21e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—KRAS—uterine cancer	2.04e-06	1.21e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—HRAS—uterine cancer	2.03e-06	1.2e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—HRAS—uterine cancer	2.02e-06	1.2e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—MTHFR—uterine cancer	2.01e-06	1.19e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—PIK3CA—uterine cancer	1.97e-06	1.17e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—VEGFA—uterine cancer	1.94e-06	1.15e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NRAS—uterine cancer	1.92e-06	1.14e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—KRAS—uterine cancer	1.91e-06	1.13e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—uterine cancer	1.9e-06	1.13e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTEN—uterine cancer	1.9e-06	1.13e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—AKT1—uterine cancer	1.89e-06	1.12e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—AKT1—uterine cancer	1.89e-06	1.12e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—PIK3CA—uterine cancer	1.88e-06	1.11e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTEN—uterine cancer	1.86e-06	1.1e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PIK3CA—uterine cancer	1.83e-06	1.09e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—HRAS—uterine cancer	1.82e-06	1.08e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—uterine cancer	1.82e-06	1.08e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PIK3CA—uterine cancer	1.81e-06	1.08e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—EP300—uterine cancer	1.81e-06	1.08e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—AKT1—uterine cancer	1.79e-06	1.06e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—AKT1—uterine cancer	1.78e-06	1.06e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.77e-06	1.05e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—EP300—uterine cancer	1.77e-06	1.05e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—AKT1—uterine cancer	1.76e-06	1.05e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—AKT1—uterine cancer	1.76e-06	1.05e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—PIK3CA—uterine cancer	1.75e-06	1.04e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—HRAS—uterine cancer	1.74e-06	1.03e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—uterine cancer	1.7e-06	1.01e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—KRAS—uterine cancer	1.65e-06	9.79e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HRAS—uterine cancer	1.62e-06	9.64e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTEN—uterine cancer	1.61e-06	9.56e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—AKT1—uterine cancer	1.61e-06	9.55e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—MTHFR—uterine cancer	1.55e-06	9.22e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—EP300—uterine cancer	1.54e-06	9.11e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—AKT1—uterine cancer	1.53e-06	9.1e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—PIK3CA—uterine cancer	1.51e-06	8.99e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—AKT1—uterine cancer	1.5e-06	8.87e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—AKT1—uterine cancer	1.48e-06	8.8e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—uterine cancer	1.47e-06	8.7e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTEN—uterine cancer	1.44e-06	8.53e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—AKT1—uterine cancer	1.43e-06	8.51e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTEN—uterine cancer	1.4e-06	8.33e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HRAS—uterine cancer	1.4e-06	8.32e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—EP300—uterine cancer	1.37e-06	8.13e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PIK3CA—uterine cancer	1.34e-06	7.96e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—EP300—uterine cancer	1.34e-06	7.94e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTEN—uterine cancer	1.32e-06	7.85e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PIK3CA—uterine cancer	1.31e-06	7.78e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTEN—uterine cancer	1.31e-06	7.78e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—EP300—uterine cancer	1.26e-06	7.48e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—EP300—uterine cancer	1.25e-06	7.42e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—AKT1—uterine cancer	1.24e-06	7.34e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PIK3CA—uterine cancer	1.14e-06	6.74e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTEN—uterine cancer	1.12e-06	6.65e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—AKT1—uterine cancer	1.1e-06	6.51e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—AKT1—uterine cancer	1.07e-06	6.36e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—EP300—uterine cancer	1.07e-06	6.34e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PIK3CA—uterine cancer	1.01e-06	6.02e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PIK3CA—uterine cancer	9.89e-07	5.87e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PIK3CA—uterine cancer	9.32e-07	5.53e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—AKT1—uterine cancer	9.28e-07	5.51e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PIK3CA—uterine cancer	9.24e-07	5.49e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTEN—uterine cancer	8.64e-07	5.13e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—AKT1—uterine cancer	8.28e-07	4.92e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—EP300—uterine cancer	8.24e-07	4.89e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—AKT1—uterine cancer	8.08e-07	4.8e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PIK3CA—uterine cancer	7.9e-07	4.69e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—AKT1—uterine cancer	7.62e-07	4.52e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—AKT1—uterine cancer	7.55e-07	4.48e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—AKT1—uterine cancer	6.45e-07	3.83e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PIK3CA—uterine cancer	6.1e-07	3.62e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—AKT1—uterine cancer	4.98e-07	2.96e-06	CbGpPWpGaD
